ARCH Venture Management, LLC
CIK: 0001274403Latest portfolio: $651.7M · Q4 2025
Holdings
9
Total Value
$651.7M
New Positions
1
Closed Positions
1
Top Holdings
| # | Stock | Shares | Value | % Portfolio | Change | Type |
|---|---|---|---|---|---|---|
| 1 | MAZEMAZE THERAPEUTICS INC. | 4,120,053 | $170.7M | 26.19% | — | |
| 2 | BEAMBEAM THERAPEUTICS INC. | 4,540,132 | $125.9M | 19.31% | — | |
| 3 | RAPPRAPPORT THERAPEUTICS INC. | 3,728,738 | $113.1M | 17.36% | — | |
| 4 | LYELLYELL IMMUNOPHARMA INC. | 2,759,072 | $84.9M | 13.03% | — | |
| 5 | VIRVIR BIOTECHNOLOGY INC. | 12,916,663 | $77.9M | 11.95% | — | |
| 6 | ERASERASCA INC. | 11,055,554 | $41.1M | 6.31% | — | |
| 7 | GOSSGOSSAMER BIO INC. | 8,055,916 | $25.0M | 3.83% | — | |
| 8 | TXG10X GENOMICS INC. | 737,539 | $12.0M | 1.85% | NEW | |
| 9 | QTTBQ32 BIO INC. | 320,482 | $1.1M | 0.16% | — |
Quarterly Changes
Sector Breakdown
Healthcare100.0% ($1.7069312585211314e+37T)
Filing History
Fund Information
ARCH Venture Management, LLC is an institutional investment manager that files 13F reports with the SEC. As of the Q4 2025 filing, the fund reported a portfolio valued at $651.7M across 9 holdings. The largest position is MAZE THERAPEUTICS INC. (MAZE), representing 26.2% of the portfolio. Compared to the previous quarter, the fund opened 1 new positions and closed 1 positions. 13F filings are required quarterly disclosures that provide transparency into the holdings of institutional investment managers with at least $100 million in qualifying assets.